ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Nurix Therapeutics Inc

Nurix Therapeutics Inc (NRIX)

20.74
0.28
(1.37%)
Closed June 28 3:00PM
20.74
0.00
(0.00%)
After Hours: 6:26PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
20.74
Bid
20.00
Ask
22.48
Volume
528,514
20.051 Day's Range 21.11
4.22 52 Week Range 22.4388
Market Cap
Previous Close
20.46
Open
20.63
Last Trade
7
@
21.04
Last Trade Time
Financial Volume
US$ 10,987,334
VWAP
20.7891
Average Volume (3m)
1,181,700
Shares Outstanding
49,150,794
Dividend Yield
-
PE Ratio
-7.08
Earnings Per Share (EPS)
-2.93
Revenue
76.99M
Net Profit
-143.95M

About Nurix Therapeutics Inc

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted pr... Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dover, Delaware, USA
Founded
1970
Nurix Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker NRIX. The last closing price for Nurix Therapeutics was US$20.46. Over the last year, Nurix Therapeutics shares have traded in a share price range of US$ 4.22 to US$ 22.4388.

Nurix Therapeutics currently has 49,150,794 shares outstanding. The market capitalization of Nurix Therapeutics is US$1.02 billion. Nurix Therapeutics has a price to earnings ratio (PE ratio) of -7.08.

NRIX Latest News

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and...

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
12.1611.625403659818.5822.438818.1759162183120.96514702CS
45.4335.467015022915.3122.438814.44122498817.95831717CS
125.9940.610169491514.7522.438811.9118170015.97910646CS
2610.81108.862034249.9322.43887.6597738813.97970452CS
5210.97112.2824974419.7722.43884.2274598511.79634463CS
156-9.16-30.63545150529.937.4254.2252000014.60793803CS
2600.492.4197530864220.2552.384.2247179517.50996456CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SFDNXT Energy Solutions Inc
$ 0.285
(35.71%)
150.4k
ASNDAscendant Resources Inc
$ 0.045
(28.57%)
1,000
NCFNorthcliff Resources Ltd
$ 0.025
(25.00%)
130k
FANSFansUnite Entertainment Inc
$ 0.055
(22.22%)
1.64M
FLOWFlow Beverage Corp
$ 0.215
(19.44%)
204.27k
SMCSulliden Mining Capital Inc
$ 0.01
(-33.33%)
4k
DNDelta 9 Cannabis Inc
$ 0.01
(-33.33%)
539.1k
GMTNGold Mountain Mining Corp
$ 0.03
(-25.00%)
173.85k
SCYScandium International Mining Corp
$ 0.015
(-25.00%)
15.8k
GVCGlacier Media Inc
$ 0.09
(-18.18%)
150.44k
CNQCanadian Natural Resources Ltd
$ 48.83
(0.99%)
6.59M
CMCanadian Imperial Bank of Commerce
$ 66.46
(0.77%)
5.51M
BTEBaytex Energy Corp
$ 4.75
(2.59%)
5.33M
TRPTC Energy Corporation
$ 52.80
(-0.02%)
4.35M
BNSBank of Nova Scotia
$ 62.40
(0.11%)
4.31M

NRIX Discussion

View Posts
Monksdream Monksdream 6 days ago
NRIX new 52 week high
👍️0
Monksdream Monksdream 4 weeks ago
NRIX more new highs up ahead
👍️0
Monksdream Monksdream 3 months ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 3 months ago
NRIX new 52 hi
👍️0
Monksdream Monksdream 4 months ago
NRIX new 52 week high
👍️0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NASDAQ/nurix-therapeutics-NRIX/stock-news/88898489/cathie-wood-doubles-down-on-these-2-strong-buy
👍️0
infamous infamous 3 years ago
what the F is wrong with this fkn stock? does it ever go up???
👍️0
Phosphene Phosphene 4 years ago
CEO: Dr. Arthur T. Sands

https://www.nurixtx.com/arthur-t-sands-m-d-ph-d/
👍️0
Phosphene Phosphene 4 years ago
Strategic partnerships with Sanofi and Gilead Sciences Inc.

https://www.nurixtx.com/research-development/strategic-partnerships/

Wellington and Baker Brothers are among Institutional Ownership and Shareholders:

https://fintel.io/so/us/nrix?__cf_chl_jschl_tk__=c9a7439112376e9f70de91c1316dfcc7e26d3519-1607403189-0-AT-0XpHMlNGWmcEzimwDKelDxLnOK6gsd8IihalGD8DcDe76KQlrWnh2Q1G3OLjfsidXSQyjVOkcCg3lXIXgKu6RIlw8DMusjRJpgnTzQP2qkahd1WSCP-5At2BI9Udfzc2vqpmlZOV3prAMIdFIh1_urJuBNq7hGlM4oSEJKFEFs8WDerUagukeDe9yBmvVg0Ne17vR8ByRaN-BlyHHxPWeTerJ_ZHoD1jnsxFYInhjhkK-XNkhe3BJ0Wzq3782kDVndNMNsb1glMkmm_NlSnc8Xbwve1nF3nGShcpgUxA-nefEgd9L74SzGXF1WftTIX4HYgwtb1BRzq82RClNfm9dr9Xb-hKp3xKKiYL4k9KfqV9OAePxDJoYgKqLUziXoA
👍️0
Phosphene Phosphene 4 years ago
Data support a planned clinical trial of NX-2127 in B-cell malignancies

http://www.globenewswire.com/news-release/2020/12/07/2140737/0/en/Nurix-Therapeutics-Presents-Preclinical-Data-at-62nd-American-Society-of-Hematology-ASH-Annual-Meeting-and-Exposition.html
👍️0